Andrew Witty

Showing 13 posts of 13 posts found.

Andrew Witty takes on a new CEO position

March 15, 2018
Medical Communications Andrew Witty, GSK, Optum, UnitedHealth, biotech, drugs, pharma, pharmaceutical

Andrew Witty, who made his name working his way up the ranks at GSK to become its CEO, has revealed …


Witty to lead way in fast-tracking medicine through UK system

November 3, 2017
Medical Communications AAR, Andrew Witty, GSK, biotech, drugs, pharma, pharmaceutical

The UK government has announced its response to the Accelerated Access Review that was published last year, with former GSK …


Witty, Ex-CEO of GSK, keeps busy with two new roles in two days

September 21, 2017
Medical Communications : Pharma, Andrew Witty, GSK, biotech, drugs, pharma, pharmaceutical

It was always unlikely that Andrew Witty, former CEO of GSK, would take his ‘retirement’ from the company literally, but …


UK pharma would benefit by remaining in EU, says ABPI

May 9, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Andrew Witty, EU, brexit, letter, observer, pascal soriot, remain, stay

With the EU vote approaching, the Association of the British Pharmaceutical Industry (ABPI) has brought together 93 signatories, including the …


GlaxoSmithKline opens new £56 million facility in Hertfordshire

April 19, 2016
Manufacturing and Production Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware

GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England. The facility in Ware will create 150 …

Sir Andrew Witty announces decision to step down as CEO of GSK

March 17, 2016
Medical Communications, Research and Development Andrew Witty, GSK, GlaxoSmithKline, Neil Woodford, Sir Andrew Witty, Witty, gsk break up, gsk split, retirement, steps down

Sir Andrew Witty has announced his decision to retire from his role as chief executive officer of pharmaceutical giant, GlaxoSmithKline …

Photo story: GSK’s 2012 legacy

May 30, 2012
Research and Development Andrew Witty, GSK, Olympics 2012

Tuesday May 29, 2012: GlaxoSmithKline chief executive, Sir Andrew Witty makes a speech at a conference at the company’s headquarters …

Emerging markets no haven from HTA, says NICE

February 15, 2012
Andrew Witty, GSK, NICE, NICE International

The head of NICE says pharma will face health technology assessment barriers in every country – including fast-growing developing markets. …

GSK’s Andrew Witty knighted

January 3, 2012
Sales and Marketing Andrew Witty, GSK

GlaxoSmithKline chief executive Andrew Witty and former ABPI director general Richard Barker were among the recipients in the 2012 New …

Pharma engages HTA bodies in early-stage drug discussions

October 27, 2010
Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta

Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …


GSK’s Andrew Witty appointed president of EFPIA

January 5, 2010
Research and Development, Sales and Marketing Andrew Witty, EFPIA, GSK, appointment, research and development, sales and marketing

GlaxoSmithKline chief executive Andrew Witty has been appointed president of EFPIA.He previously served as vice-president of the European industry association for two years and takes …

Latest content